No licensed hantavirus vaccine exists for general use in the US or most Western countries as of mid-2026, despite recent Andes virus outbreaks with confirmed cases and person-to-person transmission potential. Early-stage candidates, including DNA and mRNA platforms from preclinical studies and limited Phase 1 trials, have shown immunogenicity in animal models and small human cohorts, but no Phase 3 efficacy trials are underway. Vaccine development timelines, regulatory requirements for safety data on rare rodent-borne pathogens, and the absence of large-scale field testing amid low baseline incidence keep market-implied odds for approval this year near zero. Unexpected emergency authorization or accelerated regulatory pathways could shift consensus if new outbreak data emerge, though current surveillance from CDC and WHO shows limited risk.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% szansa
$129,623 Wol.
$129,623 Wol.
Dec 31, 2026
6% szansa
$129,623 Wol.
$129,623 Wol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No licensed hantavirus vaccine exists for general use in the US or most Western countries as of mid-2026, despite recent Andes virus outbreaks with confirmed cases and person-to-person transmission potential. Early-stage candidates, including DNA and mRNA platforms from preclinical studies and limited Phase 1 trials, have shown immunogenicity in animal models and small human cohorts, but no Phase 3 efficacy trials are underway. Vaccine development timelines, regulatory requirements for safety data on rare rodent-borne pathogens, and the absence of large-scale field testing amid low baseline incidence keep market-implied odds for approval this year near zero. Unexpected emergency authorization or accelerated regulatory pathways could shift consensus if new outbreak data emerge, though current surveillance from CDC and WHO shows limited risk.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Rynek otwarty: May 4, 2026, 10:39 AM ET
Wolumen
$129,623Data zakończenia
Dec 31, 2026Rynek otwarty
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No licensed hantavirus vaccine exists for general use in the US or most Western countries as of mid-2026, despite recent Andes virus outbreaks with confirmed cases and person-to-person transmission potential. Early-stage candidates, including DNA and mRNA platforms from preclinical studies and limited Phase 1 trials, have shown immunogenicity in animal models and small human cohorts, but no Phase 3 efficacy trials are underway. Vaccine development timelines, regulatory requirements for safety data on rare rodent-borne pathogens, and the absence of large-scale field testing amid low baseline incidence keep market-implied odds for approval this year near zero. Unexpected emergency authorization or accelerated regulatory pathways could shift consensus if new outbreak data emerge, though current surveillance from CDC and WHO shows limited risk.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Wolumen
$129,623Data zakończenia
Dec 31, 2026Rynek otwarty
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No licensed hantavirus vaccine exists for general use in the US or most Western countries as of mid-2026, despite recent Andes virus outbreaks with confirmed cases and person-to-person transmission potential. Early-stage candidates, including DNA and mRNA platforms from preclinical studies and limited Phase 1 trials, have shown immunogenicity in animal models and small human cohorts, but no Phase 3 efficacy trials are underway. Vaccine development timelines, regulatory requirements for safety data on rare rodent-borne pathogens, and the absence of large-scale field testing amid low baseline incidence keep market-implied odds for approval this year near zero. Unexpected emergency authorization or accelerated regulatory pathways could shift consensus if new outbreak data emerge, though current surveillance from CDC and WHO shows limited risk.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania